Innovent Biologics Inc. has announced the grant of 20,800 share options and restricted shares to five grantees, including independent non-executive Director Dr. Sherwin, as part of their 2024 Share Scheme. The company aims to align the interests of its key personnel with its strategic goals. Notably, the restricted shares granted to Dr. Sherwin come without performance targets, reflecting the company's commitment to maintaining the independence and objectivity of its independent directors. The announcement was made on August 29, 2025, by Dr. De-Chao Michael Yu, Chairman and Executive Director of Innovent Biologics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.